Sign in or Register

Creative Biolabs has successfully developed SARS, MERS and other anti-viral antibodies in the past to assist scientific research. Facing the difficult COVID-19, Creative Biolabs actively invests in antibody development to assist researchers to better understand the characteristics of 2019-nCoV and drug development. Currently, Creative Biolabs is proud to offer an extensive line of research antibodies to support the study of SARS-CoV-2/COVID-19, several of which were validated using virus-infected cell lysates.

Explore the collections of SARS-CoV-2/COVID-19 antibodies >

Rat AKI Antibody Array (Membrane, 7 Targets) (Y0142) (AbAr-0142-YC)

Antibody array is a specific form of protein microarray. In this technology, capture antibodies spotted on membranes or glass slide bind to specific target proteins present in the sample. Captured proteins are visualized using chemiluminescent or Laser Scanner. The signal produced is proportional to the amount of analyte bound. The Rat AKI Antibody Array detects 7 rat Cytokines. It is suitable for all liquid sample types.
Target Array
AKI Array
TIM-1 (KIM-1), TIMP-1, FABP1, VEGF-A, MCP-1 (CCL2), Cystatin C, Lipocalin-2 (NGAL)
Species Reactivity
Sample Type
Serum, Plasma, Cell Culture Supernatant, Cell Lysates, Tissue Lysates
Multiplex Protein Detection
Assay Type
Solid Support
Detection Assay
Protocol Outline
Block membranes
Incubate with Sample
Incubate with Biotinylated Detection Antibody Cocktail
Incubate with HRP-Conjugated Streptavidin
Incubate with Detection Buffers
Image with chemiluminescent imaging system
Perform densitometry and analysis
Antibody Array Membrane
Labeling Reagent
Blocking Buffer
Wash Buffer
Detection Buffer
Detection Cocktail
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Once thawed, please keep reagents under suitable conditions respectively. Do not use past expiration date.
Serum cytokines are increased in patients with acute kidney injury (AKI), and increased serum interleukin (IL)-6, IL-8 and IL-10 predict mortality in patients with AKI. Cytokines are not just biomarkers of poor outcomes, but mediate deleterious systemic effects. Pro-inflammatory cytokines such as IL-6 and IL-8 mediate distant organ injury and contribute to the systemic inflammatory response syndrome and acute lung injury (ALI). Anti-inflammatory cytokines such as IL-10 may contribute to immune stasis and impair the ability to fight infection. These cytokine-mediated deleterious effects may contribute to the high mortality of patients with AKI. Thus, a better understanding of the production and clearance of cytokines in AKI may shed light onto potential therapeutic treatments for patients with AKI.
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Submit a review Submit a review and you will get a coupon.
0 reviews

Please try the standard protocols which include: protocols, troubleshooting and guide.

Click here to view the protocols, troubleshooting and guide.